Apex Labs is developing psilocybin-based pharmaceuticals aimed at treating depression and PTSD, addressing the limitations of current antidepressant therapies which have a 40-60% effectiveness rate and often cause unwanted side effects. The company focuses on creating clinically evaluated drugs that can be prescribed by physicians globally, aiming to establish a new standard of care in mental health treatment.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antidepressant therapies have a 40-60% effectiveness rate, and 50% of treated individuals report unwanted side effects. This necessitates the exploration of new treatment options for depression and PTSD.
Solution
Apex Labs is developing clinically evaluated psilocybin-based pharmaceuticals to address the unmet needs in depression and PTSD treatment. The company aims to establish a new standard of care in mental health by creating drugs that can be prescribed by physicians globally. By focusing on clinically proven treatments, Apex Labs seeks to provide more effective and tolerable options for patients suffering from these conditions.
Target Audience
The primary target audience includes individuals suffering from depression and PTSD, as well as physicians seeking more effective treatment options for their patients.
Features
- Development of psilocybin-based pharmaceuticals
- Focus on clinically evaluated drugs for depression and PTSD
- Aims for global accessibility and prescription by physicians